Drug Trial Radar · NCT01839487
PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer
Last checked: Nov 19, 2026Latest source record: Jul 20, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
279
Actual
Start
May 14, 2013
Primary completion
May 1, 2018
Study completion Sep 26, 2018
Sponsor
- Lead sponsor
- Halozyme TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Apr 25, 2013
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed to compare the treatment effect of PEGPH20 combined with nab-paclitaxel (NAB) and gemcitabine (GEM) \[PAG\] to NAB and GEM \[AG\] in participants with Stage IV previously untreated pancreatic ductal adenocarcinoma (PDA). The study will have 2 run-in phases, one for each formulation of PEGPH20 (original and new formulations), and a Phase 2 portion. The 2 run-in phases will evaluate the safety and tolerability of the PAG treatment using the original and new succinic acid PEGPH20 formulation, respectively, compared with AG treatment. Phase 2 will have 2 stages due to a partial clinical hold that occurred from April through July 2014. The participants will be randomized in 3:1 for the run-in phases. The first stage will randomize participants in a 1:1 ratio. The second stage will randomize participants in a 2:1 ratio (PAG:AG). This is an open-label study. To minimize bias to the progression-free survival endpoint, disease progression will be based on the assessment of the Central Imaging Reader (CIR). Determination of clinical progression by the Investigator without corresponding CIR confirmation will be documented with the relevant signs and symptoms.
Conditions
- Metastatic Pancreatic Cancer
Interventions
PEGPH20Drug
PEGPH20 will be administered as per the dose and schedule specified in the respective arms.
Nab-paclitaxelDrug
Nab-paclitaxel will be administered as per the dose and schedule specified in the respective arms.
GemcitabineDrug
Gemcitabine will be administered as per the dose and schedule specified in the respective arms.
DexamethasoneDrug
Dexamethasone will be administered as per the dose and schedule specified in the respective arms.
EnoxaparinDrug
Enoxaparin will be administered as per the dose and schedule specified in the respective arms.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS)Time frame: From the date of randomization until disease progression or death from any cause (maximum exposure: 30.72 months for PAG, and 20.27 months for AG)
- Percentage of Participants in the PAG Arm Who Experienced Any Thromboembolic (TE) Event in Stage 2 of the StudyTime frame: From first exposure to any study drug (PEGPH20, NAB, GEM) through 30 days after end of treatment visit (maximum exposure: 30.72 months for PAG)
Locations
51 sites in 1 country. Site status is shown where the registry gives one.
Alabama Oncology
Birmingham, Alabama
University of South Alabama Mitchell Cancer Institute
Mobile, Alabama
Banner MD Anderson Cancer Center
Gilbert, Arizona
Mayo Clinic - Scottsdale
Scottsdale, Arizona
Arizona Oncology Associates, PC
Tucson, Arizona
Highlands Oncology Group
Fayetteville, Arkansas
Providence St Joseph Medical Center
Burbank, California
Scripps Cancer Center
La Jolla, California
UCSD - Moore's Cancer Center
La Jolla, California
Cedars-Sinai Medical Center
Los Angeles, California
University of California Medical Center
Orange, California
Pacific Hematology Oncology Associates
San Francisco, California
Saint Helena Hospital
St. Helena, California
The Oncology Institute of Hope and Innovation
Whittier, California
University of Colorado Cancer Center
Aurora, Colorado
Rocky Mountain Cancer Center
Denver, Colorado
Stamford Hospital
Stamford, Connecticut
Georgetown University Medical Center
Washington D.C., District of Columbia
University of Miami, Sylvester comprehensive Cancer Center
Miami, Florida
H. Lee Moffit Cancer Center
Tampa, Florida
Piedmont Hospital
Atlanta, Georgia
Loyola University Medical Center
Maywood, Illinois
Norton Cancer Institute - Norton HealthCare Pavilion
Louisville, Kentucky
Johns Hopkins University Hospital
Baltimore, Maryland
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Lahey Clinic
Burlington, Massachusetts
University of Mass Medical School
Worcester, Massachusetts
University of Michigan
Ann Arbor, Michigan
Virginia Piper Cancer Institute
Minneapolis, Minnesota
Unniversity of Minnesota
Minneapolis, Minnesota
Research Medical Center
Kansas City, Missouri
Washington University School of Medicine
St Louis, Missouri
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada
St. Joseph's Regional Medical Center
Paterson, New Jersey
Roswell Park Cancer Institute
Buffalo, New York
North Shore Long Island Jewish Health System
Lake Success, New York
Mount Sinai Medical Center
New York, New York
Columbia University Medical Center
New York, New York
University of Rochester
Rochester, New York
Gabrail Cancer Center
Canton, Ohio
Showing 40 of 51 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.